MAM
CBIO

Meeder Asset Management’s Crescent Biopharma CBIO Stock Holding History

Meeder Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8
Closed -$4K – 2391
2019
Q4 		$4K Sell
8
-28
-78% -$15.2K ﹤0.01% 1841
2019
Q3 		$16K Buy
+36
New +$23.2K ﹤0.01% 1383
2018
Q1 		– Sell
-1
Closed -$1K – 1628
2017
Q4 		$1K Hold
1
– – ﹤0.01% 1568
2017
Q3 		$1K Sell
1
-3
-75% -$3.52K ﹤0.01% 1546
2017
Q2 		$5K Sell
4
-3
-43% -$2.48K ﹤0.01% 1191
2017
Q1 		$4K Buy
7
+5
+250% +$3.07K ﹤0.01% 1157
2016
Q4 		$1K Buy
+2
New +$1.25K ﹤0.01% 954

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meeder Asset Management's CBIO Position: Q1 2020 in Review

Meeder Asset Management sold out of Crescent Biopharma (CBIO) in Q1 2020, closing a stake of 8 shares — an estimated $4K sold.

Meeder Asset Management first reported a position in CBIO in Q4 2016 and held it in 7 quarters. The position peaked at $16K in Q3 2019. 76 funds tracked by Wall St. Rank hold CBIO as of Q1 2020.

  • Meeder Asset Management reported no remaining Crescent Biopharma position as of Q1 2020 after selling out during the quarter.
  • Meeder Asset Management sold 8 Crescent Biopharma shares in Q1 2020, an estimated $4K.
  • Meeder Asset Management first reported a position in Crescent Biopharma in Q4 2016 and held it in 7 quarters.
  • Meeder Asset Management's Crescent Biopharma position peaked at $16K in Q3 2019.
  • 76 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2020.

Based on Meeder Asset Management's 13F filing for Q1 2020, filed 15 May 2020.